Central vasopressin: dendritic and axonal secretion and renal actions

Daniel G. Bichet¹,²

¹Department of Medicine, University of Montreal, Hôpital du Sacré-Coeur de Montréal, Montréal, QC, Canada H4J 1C5 and ²Department of Physiology, University of Montreal, Hôpital du Sacré-Coeur de Montréal, Montréal, QC, Canada H4J 1C5

Correspondence and offprint requests to: Daniel G. Bichet; E-mail: daniel.bichet@umontreal.ca

Keywords: dehydration; renal sympathetic stimulation; social aspects of vasopressin and oxytocin secretion; TRPVs; vasopressin receptors

Introduction

On a daily basis, practising nephrologists evaluate hyponatremic or, on the opposite side, polyuric states using physio-pathological concepts related to central vasopressin secretion and water conservation by the kidneys. The purpose of this review is to highlight new basic and clinical developments describing the hypothalamic release and peripheral renal actions of the antidiuretic hormone, arginine-vasopressin. The classical vasopressin neuroendocrine pathway involves the axonal release of vasopressin from the neurohypophysis directly into the circulation. From there, vasopressin acts on V1 and V2 receptors to regulate blood volume and peripheral resistance. In the second neuronal pathway, vasopressin is released from axonal projections of paraventricular parvocellular neurons into the rostral ventrolateral medulla, nucleus tractus solitarius and intermediolateral column of the spinal cord, areas responsible for the integration of peripheral sympathetico-vagal outflow [1, 2] (Figure 1). A third source of vasopressin is the neuronal cell bodies and dendrites of vasopressinergic neurons [3].

I will dwell here on three new aspects of vasopressin as a central and peripheral hormone:

(a) The central ‘dendritic’ release of vasopressin from magnocellular cells of paraventricular nuclei stimulates neighboring preautonomic parvocellular neurons of the same nuclei bearing vasopressin V1a receptors and contributes to an increased renal sympathetic outflow: as a consequence, a dehydrated patient will have increased water reabsorption and renal vasoconstriction; both actions contribute to restore volume homeostasis [4] (Figure 2).

(b) The central, ‘axonal’ release of vasopressin and oxytocin targeting the brain amygdala expressing vasopressin and oxytocin receptors. Here, oxytocin decreases anxiety and stress and facilitates social encounters, maternal care and the extinction of conditioned avoidance behavior in rodents. At the same anatomical level, activation of vasopressin receptors will have opposite effects: vasopressin enhances aggressiveness, anxiety, stress levels and the consolidation of memory [5, 6]. Other central projections of vasopressinergic neurons towards the ventral pallidum, lateral septum, retrosplenial cortex and anterior hypothalamus participate in pair bonding in monogamous voles and possibly in humans [7, 8].

(c) After release from the axonal nerve terminals, at the posterior pituitary level, circulating vasopressin will rapidly engage vasopressin V2 receptors in the principal cells of the collecting duct and lead to the rapid insertion of aquaporin 2 water channels: as a consequence, an adult patient with central diabetes insipidus treated with vasopressin will benefit from the transcellular water reabsorption of 12–14 L of final urine presented normally at the beginning of the collecting duct, his urine excretion will only be <2 L/day [9].

The neuropeptide vasopressin primary signals thus include not only plasma vasopressin but also concentration of vasopressin in the extracellular fluid of the brain [3].

Axonal vasopressin release from nerve terminals in the posterior pituitary gland into the general circulation

Anatomy of vasopressin secretion from axon terminals

Circulating plasma vasopressin is synthesized by a few (around 10 000 in the rat, 100 000 in humans) large (magnocellular) neurons whose cell bodies are located in the supraoptic and paraventricular nuclei of the hypothalamus [3]. Each magnocellular neuron has one axon that projects to the posterior pituitary, where it gives rise to ~10 000 neurosecretory endings that are packed with large dense-core vesicles (LDCV) containing the products of the vasopressin (AVP) gene: vasopressin itself, neurophysin II and copeptin. Vasopressin is small, only nine amino acids, and difficult to measure by radio immun assay; copeptin is slightly larger, amenable to a sandwich immunoluminometric assay by clinical biologists [10] and appreciated by neuroradiologists since it is responsible for the pituitary ‘bright spot’, an imperfect measure of the vasopressin content of the posterior pituitary: this hyperintensity could be lost in both central and nephrogenic
diabetes insipidus (NDI) with either low vasopressin secretion or, in NDI, with vasopressin release exhaustion [11]. Do not rely on the absence of the posterior pituitary ‘bright spot’ to confirm the diagnosis of central diabetes insipidus, but rather use it to describe the hypothalamic and posterior pituitary anatomy, look for secondary causes of central diabetes insipidus, in all patients with central unexplained polyuria.

**Stimuli of vasopressin secretion and thirst perception**

The two main stimuli of vasopressin secretion and thirst perception are dehydration and volume depletion [12]. Dehydration is sensed by transient receptor vanilloid-type (TRPV1) channels inserted at the plasma membrane of magnocellular cells but also in osmoreceptive cells of the organum vasculosum of the lamina terminalis (OVLT) [1] (Figure 3). Cells of the OVLT are perfect osmoreceptors [14]. Cell shrinking induced by dehydration generates action potentials at the cell bodies of OVLT and magnocellular neurons, which propagate down their axons to invade nerve terminals. Depolarization of the nerve terminals triggers the exocytosis of LDCVs which release their contents into the general circulation. Neurons of the OVLT project to the anterior cingulate and insular cortex directly and through thalamic relays and are responsible for the thirst sensation arousal and its behavioral effects [1]. Thirst and vasopressin release are also stimulated byafferent inputs generated through a decrease in effective blood volume perceived by high- and low-pressure receptors and ascending through the IX and X nerves (Figure 1). This central thirst perception originating from stretch receptors at the membrane surface of ‘perfect’ osmoreceptor cells in the OVLT, SON and PVN is fascinating: the five basic tastes (sour, sweet, umami, salty, bitter) are recognized by specific receptors on taste bud cells of papillae of the tongue [15], but water is not recognized by a specific receptor or channel there. Rather, dehydration signals are transferred to conscious brain areas in the anterior cingulate cortex and insula (Figure 1) [1].

**The last millisecond in the life of a large dense-core vesicle containing vasopressin for synaptic or dendritic release**

Regulated exocytosis of LDCVs to the nerve terminal membrane involves at least two membrane proteins synaptogamin and synaptobrevin/vesicle-associated membrane protein 2 (VAMP-2) of LDCVs and two proteins of the axon membrane, syntaxin-1 and soluble N-ethylmaleimide attachment protein of 25 kDa (SNAP-25). The general mechanism of membrane
Dendritic, hormone-like, intracerebral release of vasopressin: homeostatic responses and social recognition

Dendrites account for up to 90% of a neuron’s surface area, and dendrites from magnocellular cells are the
predominant source of vasopressin released in the brain (Figure 2) [3].

The release of vasopressin from dendrites and not the synaptic/axonal release of vasopressin explain the mismatches between vasopressin (peptidergic) innervation and V1a/b receptor distribution in the brain: there are no projections of vasopressin neurons in many areas of the brain, yet they respond to vasopressin stimulation and are endowed with V1a/b receptors. Mismatches for many other brain peptides seem to be more the norm than the exception [3]. Dendritic release of peptides can generate a prolonged hormone-like signal in the brain that can be self-sustaining. Vasopressin will be released in the extracellular brain compartment, its concentration, as measured by microdialysis experiments, has been shown to be as high as 1000 pg/mL, compared with usual plasma concentrations <10 pg/mL.

At least three populations of vasopressin-producing neurons demonstrate physiological responses through their dendritic release of vasopressin:

(a) vasopressin neurons of the paraventricular magnocellular nuclei, responding to graded hypertonic intracarotid infusions of hypertonic solutions, release dendritic vasopressin stimulating neighboring parvocellular preautonomic neurons of the same nucleus bearing vasopressin V1a receptors and contribute to an increased renal sympathetic outflow [4]. This is an orchestrated homeostatic response within paraventricular nuclei aimed to respond to dehydration by both release of vasopressin and maintenance of blood pressure by the activation of the sympathetic nervous system (Figure 2).

(b) the vasopressin neurons of the suprachiasmatic nuclei release vasopressin from their dendrites as well as from their nerve terminals and this release contributes to the CSF concentration of vasopressin which shows a circadian rhythmicity implying widespread diffusion of vasopressin from these suprachiasmatic nuclei as well from the close-by magnocellular supra-optic neurons [20].

(c) interneurons of the rat olfactory bulb express vasopressin and these vasopressin producing cells do not project outside the olfactory bulb, yet, they are an essential component of social recognition in rodents [21]. Vasopressin receptors, mainly V1a, are widespread in the main and accessory olfactory bulbs. Blocking the actions of vasopressin by a non-peptide V1 receptor antagonist into the olfactory bulb impairs the social recognition abilities of rats. Vasopressin is here a retrograde signal that filters activation of the mitral cells. Somato dendritic priming by vasopressin and oxytocin in the main olfactory regions may facilitate the formation of short-term social memories [22]. This is an experience-dependent release of vasopressin that could facilitate social recognition. Wacker and Ludwig are not suggesting that social recognition in humans depends on olfactory signals since vasopressin affects social behavior at many other sites (amygdala, hippocampus, striatum) as well as at the olfactory bulb, and in humans, olfactory recognition probably has a small role.

We are here entering the fascinating subject of social recognition mediated by neuropeptides including vasopressin and oxytocin. As described by Wacker and Ludwig, for social recognition to occur, an animal must recognize another animal as something it has encountered before. This involves an initial sensing of the subject, by sight, smell, touch, hearing, etc., the formation and potential
long-term consolidation of a memory, and the eventual remembrance of the subject in a subsequent encounter. Upon this recognition, an appropriate response may be aggression or affiliation depending on previous encounter and memory [22]. For example, female sheep can recognize their own offspring, allowing them, but not strange lambs, access to their milk.

‘Non-canonical’ signaling of the vasopressin V2 receptor and biased g-protein coupled receptors (GPCRs) signaling from inside

The four different vasopressin/oxytocin receptor subtypes, respectively V1a, V1b, V2 and oxytocin (OT), have been cloned in mammals, lower vertebrates and invertebrates. These are four members of the rhodopsin family within the more than 800 members of the superfamily of guanine-nucleotide (G)-protein-coupled receptors [23]. The V1a, V1b, V2, and OT receptors are strikingly similar in both size and amino acid sequence. However, the V1a, V1b, and OT receptors are selectively coupled to G-proteins of the Gq/11 family which mediate the activation of distinct isoforms of phospholipase C resulting in the breakdown of phosphoinositide lipids. The V2 receptor, on the other hand, preferentially activates the G-protein, Gs, resulting in the activation of adenyl cyclase. The classical vascular smooth muscle contraction, platelet aggregation, and hepatic glycogenolysis actions of AVP are mediated by the V1a receptor that increases cytosolic calcium. V1a receptor mRNA was found to be extensively distributed

---

**Fig. 4.** Schematic representation of the effect of vasopressin (AVP) to increase water permeability in the principal cells of the collecting duct. AVP is bound to the V2 receptor (a G-protein-linked receptor) on the basolateral membrane. The basic process of G-protein-coupled receptor signaling consists of three steps: a hepta-helical receptor that detects a ligand (in this case, AVP) in the extracellular milieu; a G-protein (G alpha-s) that dissociates into a subunit bound to GTP and beta-gamma subunits after interaction with the ligand-bound receptor; and an effector (in this case, adenylcyclase) that interacts with dissociated G-protein subunits to generate small-molecule second messengers. AVP activates adenyl cyclase, increasing the intracellular concentration of cAMP. The topology of adenyllylcyclase is characterized by two tandem repeats of six hydrophobic transmembrane domains separated by a large cytoplasmic loop, and terminates in a large intracellular tail. The dimeric structure (C1 and C2) of the catalytic domains is represented. Conversion of ATP to cAMP takes place at the dimer interface. Two aspartate residues (in C1) coordinate two metal co-factors (Mg2+ or Mn2+), represented here as two small black circles, which enable the catalytic function of the enzyme. Adenosine is shown as an open circle and the three phosphate groups (ATP) are shown as smaller open circles. Protein kinase A (PKA) is the target of the generated cAMP. The binding of cAMP to the regulatory subunits of PKA induces a conformational change, causing these subunits to dissociate from the catalytic subunits. These activated subunits (C) as shown here are anchored to an aquaporin-2 (AQP2)-containing endocytic vesicle via anA-kinase anchoring protein. The local concentration and distribution of the cAMP gradient is limited by phosphodiesterases (PDEs). Cytoplasmic vesicles carrying the water channels (represented as homotetrameric complexes) are fused to the luminal membrane in response to AVP, thereby increasing the water permeability of this membrane. The dissociation of the A-kinase anchoring protein from the endocytic vesicle is not represented. Microtubules and actin filaments are necessary for vesicle movement toward the membrane. When AVP is not available, AQP2 water channels are retrieved by an endocytic process, and water permeability returns to its original low rate. Aquaporin-3 (AQP3) and aquaporin-4 (AQP4) water channels are expressed constitutively at the basolateral membrane. Other G-protein coupled receptor, such as EP2, EP4 and the secretin receptor may also contribute to intracellular c-AMP increase (see text).
throughout the brain where AVP may act as a neurotransmitter or a neuromodulator in addition to its classical role on vascular tone [24]. Brain AVP receptors have been proposed to mediate the effect of AVP on memory and learning, antipyresis, brain development, selective aggression and partner preference in rodents, cardiovascular responsiveness, blood flow to the choroid plexus and cerebrospinal fluid production, regulation of smooth muscle tone in superficial brain vasculature and analgesia. V1b receptors are not only expressed in the anterior pituitary and kidney as originally reported, but also in the brain, thymus, heart, breast, lung and liver [25]. V2 transcripts are heavily expressed in cells of the renal collecting ducts (in humans and rodents) and in cells of the thick ascending limbs of the loops of Henle (in rodents only) [9]. The transfer of water across the principal cells of the collecting duct is described in Figure 4.

In the current ‘canonical’ model of G-protein-coupled receptor signaling, arrestin terminates receptor signaling by impairing receptor–G-protein coupling and promoting receptor internalization. The vasopressin V2 receptor does not follow this conventional desensitization paradigm since β-arrestins prolong G protein (GS)-mediated cAMP generation triggered by vasopressin [26]. This recent observation is related to NDI since there was previous evidence that a mutant vasopressin V2 receptor associated with NDI remains in the endoplasmic reticulum yet generates cAMP when challenged with a membrane-permeant agonist [27]. To increase urine osmolality in NDI patients bearing loss-of-function of the vasopressin V2 receptor, some new avenues exist, including ligands [28] that could trigger a specific stimulation of intracellular cAMP through other GPCRs, like prostanoid receptors, also expressed in principal cells of the collecting duct [29].

Conflict of interest statement. None declared.

References

1. Bourque CW. Central mechanisms of osmosensation and systemic osmoregulation. Nat Rev Neurosci 2008; 9: 519–531
2. Murphy D, Konopacka A, Hindmarch C et al. A novel hypothalamic-neurohypophyseal system: from genome to physiology. J Neuroendocrinol 2012; 24: 539–553
3. Ludwig M, Leng G. Dendritic peptide release and peptide-dependent behaviours. Nat Rev Neurosci 2006; 7: 126–136
4. Son SJ, Filosa JA, Potapenko ES et al. Dendritic peptide release mediates interpopulation crosstalk between neurosecretory and preautonomic networks. Neuron 2013; 78: 1036–1049
5. Huber D, Veinante P, Stoop R. Vasopressin and oxytocin excite distinct neuronal populations in the central amygdala. Science 2005; 308: 245–248
6. Knobloch HS, Charlet A, Hoffmann LC et al. Evoked axonal oxytocin release in the central amygdala attenuates fear response. Neuron 2012; 73: 553–566
7. Insel TR. The challenge of translation in social neuroscience: a review of oxytocin, vasopressin, and affiliative behavior. Neuron 2010; 65: 768–779
8. Insel TR. Next-generation treatments for mental disorders. Sci Transl Med 2012; 4: 155ps19
9. Kortenoeven ML, Fenton RA. Renal aquaporins and water balance disorders. Biochimica et Biophysica Acta 2014; 1840: 1533–1549
10. Fenske WK, Christ-Crain M, Horning A et al. A copeptin-based classification of the osmoregulatory defects in the syndrome of inappropriate antidiuresis. J Am Soc Nephrol 2014; doi:10.1681/ASN.2013080895
11. Ronadive SA, Ersy B, Favre H et al. Identification, characterization and rescue of a novel vasopressin-2 receptor mutation causing nephrogenic diabetes insipidus. Clin Endocrinol (Oxf) 2009; 71: 388–393
12. McKinley MJ. Thirst. In: Berntson GG, Cacioppo JT (eds). Handbook of Neuroscience for the Behavioral Sciences, Vol. 2. Hoboken: John Wiley and Sons, 2009, pp. 680–709
13. Proger-Khoutorsky M, Bourque CW. Osmosensation in vasopressin neurons: changing actin density to optimize function. Trends Neurosci 2010; 33: 76–83
14. Ciura S, Liedtke W, Bourque CW. Hypertonicity sensing in organum vasculosum laminae terminales neurons: a mechanical process involving TRPV1 but not TRPV4. J Neurosci 2011; 31: 14669–14676
15. Trivedi BP. Gustatory system: the finer points of taste. Nature 2012; 486: 52–53
16. Sudhof TC. Neurontransmitter release: the last millisecond in the life of a synaptic vesicle. Neuron 2013; 80: 675–690
17. Landgraf R, Neumann ID. Vasopressin and oxytocin release within the brain: a dynamic concept of multiple and variable modes of neuropeptide communication. Front Neuroendocrinol 2004; 25: 150–176
18. Tobin V, Schwab Y, Lelos N et al. Expression of exocytosis proteins in rat supraoptic nucleus neurons. J Neuroendocrinol 2012; 24: 629–641
19. Ferro-Novick S, Brose N. Nobel 2013 Physiology or medicine: traffic control system within cells. Nature 2013; 504: 98
20. Brown CH, Bains JS, Ludwig M et al. Physiological regulation of magnocellular neurosecretory cell activity: integration of intrinsic, local and afferent mechanisms. J Neuroendocrinol 2013; 25: 678–710
21. Tobin VA, Hashimoto H, Wacker DW et al. An intrinsic vasopressin system in the olfactory bulb is involved in social recognition. Nature 2010; 464: 413–417
22. Wacker DW, Ludwig M, Vasopressin, oxytocin, and social odor recognition. Hormones and Behavior 2012; 61: 259–265
23. Stevens RC, Cherezov V, Katritch V et al. The GPCR Network: a large-scale collaboration to determine human GPCR structure and function. Nat Rev Drug Discov 2013; 12: 25–34
24. Stoop R. Neuromodulation by oxytocin and vasopressin. Neuron 2012; 76: 142–159
25. Li JH, Jain S, McMillin SM et al. A novel experimental strategy to assess the metabolic effects of selective activation of a G (q)-coupled receptor in hepatocytes in vivo. Endocrinology 2013; 154: 3539–3551
26. Feinstein TN, Yui N, Webber MJ et al. Noncanonical control of vasopressin receptor type 2 signaling by retromer and arrestin. J Biol Chem 2013; 288: 27849–27860
27. Robben JH, Kortenoeven ML, Sze M et al. Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists. Proc Natl Acad Sci USA 2009; 106: 12195–12200
28. Shukla AK. Biasing GPCR signaling from inside. Sci Signal 2014; 7: pe3
29. Moeller HB, Rittig S, Fenton RA. Nephrogenic diabetes insipidus: essential insights into the molecular background and potential therapies for treatment. Endocr Rev 2013; 34: 278–301

Received for publication: 5.5.14; Accepted in revised form: 6.5.14